Status:
COMPLETED
Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
The Prostate Cancer Research Foundation of Canada
Conditions:
Cancer of the Prostate
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether antioxidants (vitamin E, selenium and lycopene)can change(reduce)prostate tumor size or blood flow to the prostate as determined by MRI imaging among ...
Eligibility Criteria
Inclusion
- MRI detectable prostate cancer
- PSA less than 15 ng/ml
- Gleason score \<= 7
- Prostate cancer staging T1c or T2a
Exclusion
- Concurrent use of high-dose vitamins which include selenium, lycopene, vitamin D or vitamin E
- Other malignancies diagnosed or requiring treatment within the past 5 years (except superficial bladder cancer or basal cell carcinoma)
- Current use of Proscar or Avodart
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00744549
Start Date
May 1 2008
End Date
December 1 2013
Last Update
February 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network - Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9